Has Kyong Kim, DO received payments from drug or device companies?

Yes. Drug and device makers reported $22,833 in general payments to Kyong Kim, DO across 353 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kyong Kim, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kyong Kim, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kyong Kim, DO

Interventional Pain Medicine · Lakewood, WANPI 1124009303

Payments from drug & device makers

$22,833in general payments, 2019–2025

Across 353 payments — averaging $64.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Flowonix Medical Incorporated$6K
Boston Scientific$5K
Nalu Medical, Inc.$2K
Nevro Corp.$2K
Saluda Medical Americas, Inc.$2K
Relievant Medsystems, Inc.$1K
plus $6K from 40 others

What the payments were for

Consulting fees$4,81921%
Travel & lodging$6,27227%
Food & beverage$11,74251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Flowonix Medical Incorporated	2	$5,580
Boston Scientific	50	$4,519
Nalu Medical, Inc.	9	$1,918
Nevro Corp.	44	$1,745
Saluda Medical Americas, Inc.	27	$1,582
Relievant Medsystems, Inc.	23	$1,444
Abbott	13	$1,236
Globus Medical	8	$987
Collegium Pharmaceutical, Inc.	44	$562
Medtronic(2 entities)	5	$436
Orexo US, Inc.	14	$244
AbbVie(2 entities)	13	$213
Daiichi Sankyo Inc.	12	$204
Virtus Pharmaceuticals LLC	9	$191
Inari Medical, Inc.	1	$176
Vertos Medical, Inc.	2	$155
Vertex	4	$134
Painteq LLC	2	$120
Si-bone, Inc.	4	$113
Pfizer	5	$96
Lilly USA, LLC	7	$96
IBSA Pharma Inc.	4	$93
Arbor Pharmaceuticals, Inc.	6	$90
Biohaven Pharmaceutical Holding Company Ltd.	4	$77
Scilex Pharmaceuticals Inc.	4	$70
Assertio Therapeutics, Inc.	4	$69
MDD US Operations, LLC	3	$59
Biodelivery Sciences International, Inc.	4	$57
Teva Pharmaceuticals USA, Inc.	3	$55
SPR Therapeutics, Inc	2	$55
Azurity Pharmaceuticals, Inc.	2	$49
Sentynl Therapeutics, Inc.	3	$47
DJO, LLC	1	$47
MML US, Inc.	1	$35
Biohaven Pharmaceuticals, Inc.	2	$34
Stimwave Technologies Incorporated	1	$34
Amgen(2 entities)	2	$27
Bausch Health US, LLC	1	$24
Convatec Inc.	1	$24
Fidia Pharma USA Inc.	1	$22
Pacira Pharmaceuticals Incorporated	1	$22
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$20
Biotronik NRO, Inc.	1	$20
Kowa Pharmaceuticals America, Inc.	1	$19
Itamar Medical Inc	1	$18
Novartis	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,833 in reported general payments places this provider in the 90th percentile of 30 interventional pain medicine providers in Washington.

See all interventional pain medicine providers in Washington →

Medicare billing

Part B allowed, 2024

$359,235

Medicare patients

451

Services billed

5,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MovantikNaloxegol Oxalate	20	$8,924
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	155	$5,244
Buprenorphine	12	$4,166
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	100	$3,378
Morphine Sulfate ErMorphine Sulfate	84	$2,812
Fentanyl	27	$2,477
Oxycodone Hcl	163	$2,149
Pregabalin	51	$1,055
Morphine Sulfate	29	$790
Hydromorphone Hcl	63	$766
Buprenorphine Hcl	16	$688
Methadone Hcl	35	$613
Gabapentin	50	$601
Cephalexin	57	$547
Tizanidine Hcl	18	$489

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Lakewood

Matthew McEwanLakewood$1K
Ray BakerKirkland$1.2M
Daniel NelsonKirkland$29K
Glen DavidSeattle$18K
Hyun HongOlympia$16K
Kiang Yien CheungTacoma$12K
Diyan RazaSeattle$12K
Kathy WangPuyallup$11K
Allen ShohamRichland$8K
Kashif SaeedTacoma$4K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →